O-030 Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208
Hochster H, Catalano P, O'Dwyer P, Mitchell E, Cohen D, Faller B, Kortmansky J, Kircher S, Lacy J, Lenz H, Verma U, Benson A, ECOG-ACRIN. O-030 Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208. Annals Of Oncology 2018, 29: v110. DOI: 10.1093/annonc/mdy149.029.Peer-Reviewed Original ResearchRandomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208.
Hochster H, Catalano P, O'Dwyer P, Mitchell E, Cohen D, Faller B, Kortmansky J, Kircher S, Lacy J, Lenz H, Verma U, Benson A. Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208. Journal Of Clinical Oncology 2018, 36: 3504-3504. DOI: 10.1200/jco.2018.36.15_suppl.3504.Peer-Reviewed Original Research